Kamada Ltd. (KMDA) to Issue Special Dividend of $0.14 on December 9th

Kamada Ltd. (NASDAQ:KMDA – Get Free Report) announced a special dividend on Monday, November 9th. Investors of record on Thursday, November 19th will be paid a dividend of $0.14 per share by the biotechnology company on Wednesday, December 9th. The ex-dividend date is Thursday, November 19th.

Kamada has a dividend payout ratio of 107.7% meaning the company cannot currently cover its dividend with earnings alone and is relying on its balance sheet to cover its dividend payments. Analysts expect Kamada to earn $0.58 per share next year, which means the company should continue to be able to cover its $0.42 annual dividend with an expected future payout ratio of 72.4%.

Kamada Price Performance

NASDAQ:KMDA opened at $8.11 on Tuesday. The firm has a market capitalization of $466.41 million, a P/E ratio of 18.86, a P/E/G ratio of 0.68 and a beta of 0.90. The business has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $7.99. Kamada has a 12-month low of $6.59 and a 12-month high of $9.35.

Kamada (NASDAQ:KMDA – Get Free Report) last issued its earnings results on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. The firm had revenue of $52.03 million for the quarter, compared to analyst estimates of $52.51 million. Kamada had a return on equity of 9.36% and a net margin of 12.67%. Research analysts anticipate that Kamada will post 0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its holdings in Kamada by 576.3% in the third quarter. Goldman Sachs Group Inc. now owns 399,299 shares of the biotechnology company’s stock worth $3,378,000 after purchasing an additional 340,253 shares during the period. Marshall Wace LLP increased its stake in Kamada by 150.1% during the 3rd quarter. Marshall Wace LLP now owns 188,037 shares of the biotechnology company’s stock valued at $1,591,000 after buying an additional 112,855 shares during the period. Aristides Capital LLC raised its position in shares of Kamada by 23.1% during the 3rd quarter. Aristides Capital LLC now owns 44,359 shares of the biotechnology company’s stock worth $375,000 after buying an additional 8,328 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Kamada by 14.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company’s stock worth $92,000 after buying an additional 1,346 shares in the last quarter. Finally, State of Tennessee Department of Treasury bought a new stake in shares of Kamada during the 3rd quarter worth about $60,000. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

Recommended Stories

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.